Company's Expertise in Chromogranin A Tumor Detection Marker Technology Now
Applied to Universal Technique
BAGNOLS-SUR-CEZE, France, September 23 /PRNewswire/ -- CISBIO Bioassays, a member of IBA group and a developer and marketer of diagnostic assays for the quantification of tumor markers, announced today the launch of its chromogranin A ELISA diagnostic tool, Chromoa. This ELISA kit complements CISBIO's existing chromogranin A RIACT kit and can be used by all laboratories for the detection and monitoring of neuroendocrine tumors.
Chromoa is a highly-sensitive, monoclonal antibody-based assay used to identify increased protein levels in serum when a neuroendocrine tumor is present in the human body. The most common neuroendocrine tumors affect the adrenal gland, the pancreas and the digestive track. Chromogranin A (CgA) is an increasingly essential analyte for the detection and monitoring of these tumors as well as prostate cancer, which can evolve into an aggressive, neuroendocrine form.
CGA-RIACT has long been part of CISBIO'S tumor markers detection portfolio and its analytical and clinical performance has been documented in scientific publications for over a decade. Based on the same monoclonal antibody as CGA-RIACT, Chromoa offers the same reliable results but in an ELISA format. This new kit features a longer shelf life and offers easier stock management for technicians, making it a convenient, time and cost saving alternative. Particularly suitable for laboratories that do not use radioactive kits, enzyme-linked immunosorbent assays (ELISA) have been used for the quantitative analysis of protein blood samples for two decades and can be adopted by any laboratory.
Chromoa is marketed worldwide by CISBIO and its distribution network. In the U.S., the kit is available for research use only.
About CISBIO Bioassays
CISBIO Bioassays develops, manufactures and markets diagnostic assays
for the qu
|SOURCE CISBIO Bioassays|
Copyright©2008 PR Newswire.
All rights reserved